BackFractyl Health Overview

Fractyl Health EBIT

Latest ebit for GUTS: $-120M, below the sector sector average of $-63M.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$20.82M
15.91% YoY

As of Mar 31, 2026

Annual EBIT (TTM)

-$117.60M
21.55% YoY

Trailing 12 months ending Mar 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Fractyl Health (GUTS) FAQ

The latest EBIT for GUTS is $-120M as of March 2026. That compares with $-97M in the prior-year period — down 21.5% year over year. That is below the sector sector average of $-63M. Investors often review this figure alongside Fractyl Health's historical trend and sector peers before judging valuation or financial health.

Over the past year, GUTS's EBIT moved from $-97M to $-120M — a 21.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Fractyl Health's operating scale or balance-sheet position.

Against its sector companies, GUTS currently prints $-120M for EBIT, while the sector average sits near $-63M. That is roughly 87.9% below the sector mean. Large gaps often invite a closer look at Fractyl Health's growth, margins, and balance sheet.

A EBIT figure of $-120M for GUTS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-63M. Explore the charts below for those layers of context.

After noting GUTS's EBIT ($-120M), review year-over-year change from $-97M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.